<DOC>
	<DOCNO>NCT02657434</DOCNO>
	<brief_summary>This randomize , Phase III , multicenter , open-label study design evaluate safety efficacy atezolizumab combination cisplatin carboplatin + pemetrexed compare treatment cisplatin carboplatin + pemetrexed participant chemotherapy-naive Stage IV non-squamous NSCLC . Eligible participant randomize 1:1 ratio 2 group : Arm A ( Atezolizumab + Carboplatin Cisplatin + Pemetrexed ) Arm B ( Carboplatin Cisplatin + Pemetrexed ) . The study conduct two phase : Induction Phase Maintenance Phase .</brief_summary>
	<brief_title>A Study Atezolizumab Combination With Carboplatin Cisplatin + Pemetrexed Compared With Carboplatin Cisplatin + Pemetrexed Participants Who Are Chemotherapy-Naive Have Stage IV Non-Squamous Non-Small Cell Lung Cancer ( NSCLC ) ( IMpower 132 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Histologically cytologically confirm , Stage IV nonsquamous NSCLC . Participants tumor mix nonsmall cell histology ( i.e. , squamous nonsquamous ) eligible major histological component appear nonsquamous No prior treatment Stage IV nonsquamous NSCLC . Participants sensitize mutation epidermal growth factor receptor ( EGFR ) gene anaplastic lymphoma kinase ( ALK ) fusion oncogene exclude . Participants unknown EGFR ALK status require test result screen local central laboratory Participants receive prior neoadjuvant , radiotherapy , adjuvant chemotherapy , chemoradiotherapy curative intent nonmetastatic disease must experience treatmentfree interval least 6 month randomization since last dose chemotherapy and/or radiotherapy Participants submit pretreatment tumor tissue sample available within 4 week enrollment . If tumor tissue available , participant still eligible For enrollment China extension phase , residence People 's Republic China Measurable disease , define RECIST v1.1 Adequate hematologic end organ function For woman childbearing potential : agreement remain abstinent use contraceptive method result failure rate le ( &lt; ) 1 percent ( % ) per year treatment period least 5 month last dose atezolizumab 6 month last dose cisplatin For men : agreement remain abstinent use contraceptive measure agreement refrain donate sperm CancerSpecific Exclusions Participants sensitize mutation EGFR gene ALK fusion oncogene Active untreated central nervous system ( CNS ) metastasis determine compute tomography ( CT ) magnetic resonance imaging ( MRI ) evaluation screen prior radiographic assessment Spinal cord compression definitively treat surgery and/or radiation previously diagnose treat spinal cord compression without evidence disease clinically stable great equal ( &gt; = 2 ) week prior randomization Leptomeningeal disease Uncontrolled tumorrelated pain Uncontrolled symptomatic hypercalcemia ( great [ &gt; ] 1.5 millimole/Liter ionize calcium calcium &gt; 12 milligrams/deciliter correct serum calcium &gt; upper limit normal ) Malignancies NSCLC within 5 year prior randomization Known tumor program deathligand 1 ( PDL1 ) expression status clinical study ( e.g. , participant whose PDL1 expression status determine screen entry study antiPD1 antiPD L1 antibody eligible exclude ) General Medical Exclusions : History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion protein History certain autoimmune disease History idiopathic pulmonary fibrosis , organize pneumonia , druginduced pneumonitis , idiopathic pneumonitis , evidence active pneumonitis All participant test human immunodeficiency virus ( HIV ) prior inclusion study HIVpositive participant exclude clinical study Severe infection within 4 week prior randomization Significant cardiovascular disease , New York Heart Association cardiac disease ( Class II great ) , myocardial infarction cerebrovascular accident within 3 month prior randomization , unstable arrhythmia , unstable angina Illness condition may interfere participant 's capacity understand , follow , and/or comply study procedure Exclusion Criteria Related Medications Chemotherapy : Prior treatment EGFR inhibitor ALK inhibitor Any approve anticancer therapy , include hormonal therapy within 21 day prior initiation study treatment Prior treatment cluster differentiation 137 ( CD137 ) agonists immune checkpoint blockade therapy , antiPD1 , antiPDL1 therapeutic antibody Treatment systemic immunostimulatory agent within 4 week prior randomization Treatment systemic immunosuppressive medication Exclusion Criteria Related Chemotherapy : History allergic reaction cisplatin , carboplatin , platinumcontaining compound Participants hear impairment ( cisplatin ) Grade &gt; =2 peripheral neuropathy define National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) version 4.0 criterion ( cisplatin ) Creatinine clearance ( CRCL ) &lt; 60 milliliters/minute ( mL/min ) cisplatin &lt; 45 mL/min carboplatin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>